Viatris down on late-stage trial setback for eye disorder therapy
Source: SeekingAlpha
2025-07-18 07:52:53 ET
More on Viatris
- Viatris: A Contrarian Bet With Virtually No Downside
- Viatris: The Problem With The Business Model
- Viatris Inc. (VTRS) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
- ViiV expands license to produce generic Apretude in low-income countries
- J&J wins appeals court ruling against Teva and Viatris in patent dispute over neuro drug
Read the full article on Seeking Alpha
For further details see:
Viatris down on late-stage trial setback for eye disorder therapy
Viatris Inc.
NASDAQ: VTRS
VTRS Trading
0.74% G/L:
$13.645 Last:
2,387,973 Volume:
$13.74 Open:
VTRS Latest News
April 10, 2026 06:59:00 am
Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting
March 23, 2026 06:59:00 am
Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD)
March 19, 2026 08:30:00 am
Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030
VTRS Stock Data
$18,451,353,349
1,140,252,173
N/A
503
N/A
Pharmaceuticals
Healthcare
US
Canonsburg
